Please login to the form below

Not currently logged in
Email:
Password:

Lilly reveals $1bn investment in US manufacturing site

The company also plans to invest $500m in a new biopharmaceutical manufacturing facility in Ireland

Eli Lilly

Eli Lilly has announced company plans to invest over $1bn to create a new manufacturing site in the US. The new facility in Concord will use the latest in medical device technology while increasing its manufacturing capacity, with 600 new jobs being created, including roles for highly skilled scientists, manufacturing personnel and engineers.

In 2020, Lilly invested $470m in North Carolina’s Research Triangle Park. In conjunction with this site, the new site in Concord offers proximity to local universities specialising in science, technology, engineering and maths programmes, and easy access to major transport links.

Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations, said: "Expanding our manufacturing footprint in North Carolina enables us to continue to produce today's medicines while providing additional capacity to manufacture the medicines of tomorrow."

During the past five years, Eli Lilly has invested over $4bn in manufacturing worldwide, with $2bn of this investment in the US. The company also plans to invest $500m in a new biopharmaceutical manufacturing facility in Limerick, Ireland, furthering its global presence.

Future investments from Lilly are set to include investments in manufacturing to address potential new treatment contributions into Alzheimer's disease, diabetes, cancer and autoimmune diseases.

Article by
Fleur Jeffries

31st January 2022

From: Healthcare

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...